| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,847,643 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lavidas Athanese |
Director |
– • – |
2012-06-05 |
4 |
AS |
$16.05 |
$401,280 |
D/D |
(25,000) |
100,631 |
|
- |
|
| Lavidas Athanese |
Director |
– • – |
2012-06-05 |
4 |
OE |
$6.39 |
$159,750 |
D/D |
25,000 |
125,631 |
|
- |
|
| Lavidas Athanese |
Director |
– • – |
2012-05-21 |
4 |
AS |
$16.54 |
$82,690 |
D/D |
(5,000) |
100,631 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• – – |
2012-05-03 |
4 |
OE |
$4.63 |
$277,800 |
D/D |
60,000 |
229,548 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• – – |
2012-05-02 |
4 |
AS |
$17.00 |
$329,375 |
D/D |
(19,375) |
237,856 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• – – |
2012-05-02 |
4 |
OE |
$4.19 |
$47,661 |
D/D |
11,375 |
257,231 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• – – |
2012-04-17 |
4 |
AS |
$15.00 |
$600,000 |
D/D |
(40,000) |
169,548 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• – – |
2012-04-17 |
4 |
OE |
$4.63 |
$185,200 |
D/D |
40,000 |
209,548 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• – – |
2012-04-17 |
4 |
AS |
$15.00 |
$106,665 |
D/D |
(7,111) |
233,778 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• – – |
2012-04-13 |
4 |
AS |
$14.83 |
$468,628 |
D/D |
(31,600) |
240,889 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• – – |
2012-04-12 |
4 |
AS |
$15.39 |
$262,576 |
D/D |
(17,062) |
58,770 |
|
- |
|
| Lavidas Athanese |
Director |
– • – |
2012-04-09 |
4 |
AS |
$15.76 |
$236,351 |
D/D |
(15,000) |
115,631 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• – – |
2012-04-03 |
4 |
S |
$16.18 |
$55,027 |
D/D |
(3,400) |
33,327 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• – – |
2012-04-03 |
4 |
AS |
$16.18 |
$84,134 |
D/D |
(5,200) |
272,489 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• – – |
2012-04-03 |
4 |
AS |
$16.18 |
$38,836 |
D/D |
(2,400) |
75,832 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• – – |
2012-04-03 |
4 |
AS |
$16.18 |
$68,767 |
D/D |
(4,250) |
49,781 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• – – |
2012-04-02 |
4 |
D |
$16.23 |
$30,918 |
D/D |
(1,905) |
85,095 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
36,727 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
277,689 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
78,232 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
54,031 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
87,000 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• – – |
2012-03-27 |
4 |
AS |
$16.23 |
$292,138 |
D/D |
(18,000) |
28,227 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• – – |
2012-03-26 |
4 |
AS |
$16.34 |
$425,876 |
D/D |
(26,061) |
264,689 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• – – |
2012-03-26 |
4 |
AS |
$16.00 |
$96,000 |
D/D |
(6,000) |
46,227 |
|
- |
|
703 Records found
|
|
Page 20 of 29 |
|
|
